Thermo Fisher Scientific has received FDA approval for its Oncomine Dx Target Test as a companion diagnostic for identifying patients suitable for HERNEXEOS treatment, a tyrosine kinase inhibitor developed by Boehringer Ingelheim. Through this test, clinicians can determine if non-small cell lung cancer (NSCLC) tumors carry human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain activating mutations. NSCLC, accounting for 85–90% of lung cancer cases, affects a significant portion of the population, with 2 to 4 percent of NSCLC patients having HER2 mutations.
HERNEXEOS, the first orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain mutations, was approved by the FDA in August 2025 under accelerated approval. The efficacy was based on objective response rate and duration of response, with further confirmation required in a subsequent trial. This approval marks a crucial advancement in addressing the unmet needs of patients with this specific form of NSCLC, offering hope where treatment options were previously limited.
Boehringer Ingelheim’s Senior Vice President highlighted the significance of HERNEXEOS in tackling the challenges associated with this rare form of NSCLC. The collaboration with Thermo Fisher, known for its companion diagnostics expertise, underlines the importance of accurate patient identification for targeted therapies. The Oncomine Dx Target Test, initially approved by the FDA in 2017, has since gained regulatory approvals in multiple countries for various biomarkers and therapies, offering a comprehensive solution for precision medicine.
Thermo Fisher’s commitment to expanding diagnostic solutions is evident through this recent FDA approval and its continuous efforts to enhance companion diagnostics accessibility. The company’s clinical next-generation sequencing president emphasized the success in developing timely and effective diagnostic tools, reinforcing the importance of precision medicine in improving patient outcomes. The rapid NGS solution’s approval, capable of delivering results within 24 hours, further demonstrates Thermo Fisher’s dedication to advancing diagnostic technologies for better patient care.
Key Takeaways:
– Thermo Fisher’s Oncomine Dx Target Test approval as a companion diagnostic for HERNEXEOS marks a significant milestone in NSCLC therapy.
– The FDA’s accelerated approval of HERNEXEOS for HER2-mutant NSCLC underscores the urgency to address unmet medical needs in this patient population.
– Thermo Fisher’s expertise in companion diagnostics and commitment to expanding diagnostic solutions highlight the importance of precision medicine in improving patient outcomes.
– The continuous development of advanced diagnostic tools, such as rapid NGS solutions, reflects Thermo Fisher’s dedication to enhancing patient care through innovative technologies.
Tags: regulatory
Read more on medicaldialogues.in